Pharmstandard sales revenues up 9% at 7.292 bln rubles in Q2
MOSCOW. July 25 (Interfax) - Russian pharmaceuticals company OJSC Pharmstandard earned 7.292 billion rubles in sales revenues in the second quarter of 2013, a 9% year-on-year increase, a company statement says.
H1 sales revenues amounted to 16.436 billion rubles, 2% more year-on-year. Not counting sales of third-party products, sales revenues were up 11% at 4.467 billion rubles in Q2 and 25% at 10.554 billion rubles in H1.
"Pharmaceutical sales in H1 2013 increased by 186 million rubles (+1%) up to 15.972 billion rubles vs. 15.786 billion rubles in H1 2012, with organic sales accounting for 60%, TPP [third-party products] for 37% and API for 3% in the pharmaceutical sales mix," the company said. "Organic prescription product (Rx) sales in H1 2013 grew by 672 million rubles (+30%) to reach 2.932 billion rubles. Key growth drivers were Biosulin, Combilipen and Formetine," it said.
OTC product sales were up 20% at 6.635 billion rubles. Arbidol sales increased 75% to 1.136 billion rubles in H1. "Aggregate sales of production localization segment excluding Velcade remained almost flat year-on-year," Pharmstandard said.
"Commercial TPP sales reached 3.857 billion rubles (+14%) primarily driven by Reduksin, Tamiflu and Atimos," it said.
Total medical equipment sales in H1 generated 464 million rubles, a 22% increase.
